Integration of PARP-inhibitors in ovarian cancer therapy

Poly-ADP-ribose polymerase inhibitors (PARP-I) represent one of the most attractive and promising class of biological agents studied both in relapsed ovarian cancer (OC) and in the advanced setting. The availability of this new class of drugs has changed the clinical management of OC ensuring an unp...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Antonella Pietragalla [verfasserIn] Francesca Ciccarone [verfasserIn] Camilla Nero [verfasserIn] Giovanni Scambia [verfasserIn] Domenica Lorusso [verfasserIn] Gennaro Daniele [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2020

Schlagwörter:	parp-inhibitors ovarian cancer brca1 and 2 homologous recombination deficiency dna repair

Übergeordnetes Werk:	In: Exploration of Targeted Anti-tumor Therapy - Open Exploration Publishing Inc., 2021, 1(2020), 3, Seite 171-182
Übergeordnetes Werk:	volume:1 ; year:2020 ; number:3 ; pages:171-182

Links:	Link aufrufen Link aufrufen Link aufrufen Journal toc

DOI / URN:	10.37349/etat.2020.00011

Katalog-ID:	DOAJ061689122

Internformat


LEADER	01000caa a22002652 4500
001	DOAJ061689122
003	DE-627
005	20230309013236.0
007	cr uuu---uuuuu
008	230228s2020 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.37349/etat.2020.00011 \|2 doi
035			\|a (DE-627)DOAJ061689122
035			\|a (DE-599)DOAJ79312cdaaf644f7183b9e74b8902906e
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
050		0	\|a RC31-1245
100	0		\|a Antonella Pietragalla \|e verfasserin \|4 aut
245	1	0	\|a Integration of PARP-inhibitors in ovarian cancer therapy
264		1	\|c 2020
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a Poly-ADP-ribose polymerase inhibitors (PARP-I) represent one of the most attractive and promising class of biological agents studied both in relapsed ovarian cancer (OC) and in the advanced setting. The availability of this new class of drugs has changed the clinical management of OC ensuring an unprecedented advance in such an aggressive cancer. Three oral PARP-I are currently available: olaparib, niraparib and rucaparib. Another two are in active clinical exploration: veliparib and talazoparib. Here the authors report clinical data with PARP-I with a particular emphasis on the phase II and III trials that support PARP-I approval by regulatory agencies in OC patients.
650		4	\|a parp-inhibitors
650		4	\|a ovarian cancer
650		4	\|a brca1 and 2
650		4	\|a homologous recombination deficiency
650		4	\|a dna repair
653		0	\|a Internal medicine
700	0		\|a Francesca Ciccarone \|e verfasserin \|4 aut
700	0		\|a Camilla Nero \|e verfasserin \|4 aut
700	0		\|a Giovanni Scambia \|e verfasserin \|4 aut
700	0		\|a Domenica Lorusso \|e verfasserin \|4 aut
700	0		\|a Gennaro Daniele \|e verfasserin \|4 aut
773	0	8	\|i In \|t Exploration of Targeted Anti-tumor Therapy \|d Open Exploration Publishing Inc., 2021 \|g 1(2020), 3, Seite 171-182 \|w (DE-627)174398264X \|x 26923114 \|7 nnns
773	1	8	\|g volume:1 \|g year:2020 \|g number:3 \|g pages:171-182
856	4	0	\|u https://doi.org/10.37349/etat.2020.00011 \|z kostenfrei
856	4	0	\|u https://doaj.org/article/79312cdaaf644f7183b9e74b8902906e \|z kostenfrei
856	4	0	\|u https://www.explorationpub.com/Journals/etat/Article/100211 \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/2692-3114 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 1 \|j 2020 \|e 3 \|h 171-182

Indexfelder

author_variant	a p ap f c fc c n cn g s gs d l dl g d gd
matchkey_str	article:26923114:2020----::nertooprihbtrioain
hierarchy_sort_str	2020
callnumber-subject-code	RC
publishDate	2020
allfields	10.37349/etat.2020.00011 doi (DE-627)DOAJ061689122 (DE-599)DOAJ79312cdaaf644f7183b9e74b8902906e DE-627 ger DE-627 rakwb eng RC31-1245 Antonella Pietragalla verfasserin aut Integration of PARP-inhibitors in ovarian cancer therapy 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Poly-ADP-ribose polymerase inhibitors (PARP-I) represent one of the most attractive and promising class of biological agents studied both in relapsed ovarian cancer (OC) and in the advanced setting. The availability of this new class of drugs has changed the clinical management of OC ensuring an unprecedented advance in such an aggressive cancer. Three oral PARP-I are currently available: olaparib, niraparib and rucaparib. Another two are in active clinical exploration: veliparib and talazoparib. Here the authors report clinical data with PARP-I with a particular emphasis on the phase II and III trials that support PARP-I approval by regulatory agencies in OC patients. parp-inhibitors ovarian cancer brca1 and 2 homologous recombination deficiency dna repair Internal medicine Francesca Ciccarone verfasserin aut Camilla Nero verfasserin aut Giovanni Scambia verfasserin aut Domenica Lorusso verfasserin aut Gennaro Daniele verfasserin aut In Exploration of Targeted Anti-tumor Therapy Open Exploration Publishing Inc., 2021 1(2020), 3, Seite 171-182 (DE-627)174398264X 26923114 nnns volume:1 year:2020 number:3 pages:171-182 https://doi.org/10.37349/etat.2020.00011 kostenfrei https://doaj.org/article/79312cdaaf644f7183b9e74b8902906e kostenfrei https://www.explorationpub.com/Journals/etat/Article/100211 kostenfrei https://doaj.org/toc/2692-3114 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 1 2020 3 171-182
spelling	10.37349/etat.2020.00011 doi (DE-627)DOAJ061689122 (DE-599)DOAJ79312cdaaf644f7183b9e74b8902906e DE-627 ger DE-627 rakwb eng RC31-1245 Antonella Pietragalla verfasserin aut Integration of PARP-inhibitors in ovarian cancer therapy 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Poly-ADP-ribose polymerase inhibitors (PARP-I) represent one of the most attractive and promising class of biological agents studied both in relapsed ovarian cancer (OC) and in the advanced setting. The availability of this new class of drugs has changed the clinical management of OC ensuring an unprecedented advance in such an aggressive cancer. Three oral PARP-I are currently available: olaparib, niraparib and rucaparib. Another two are in active clinical exploration: veliparib and talazoparib. Here the authors report clinical data with PARP-I with a particular emphasis on the phase II and III trials that support PARP-I approval by regulatory agencies in OC patients. parp-inhibitors ovarian cancer brca1 and 2 homologous recombination deficiency dna repair Internal medicine Francesca Ciccarone verfasserin aut Camilla Nero verfasserin aut Giovanni Scambia verfasserin aut Domenica Lorusso verfasserin aut Gennaro Daniele verfasserin aut In Exploration of Targeted Anti-tumor Therapy Open Exploration Publishing Inc., 2021 1(2020), 3, Seite 171-182 (DE-627)174398264X 26923114 nnns volume:1 year:2020 number:3 pages:171-182 https://doi.org/10.37349/etat.2020.00011 kostenfrei https://doaj.org/article/79312cdaaf644f7183b9e74b8902906e kostenfrei https://www.explorationpub.com/Journals/etat/Article/100211 kostenfrei https://doaj.org/toc/2692-3114 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 1 2020 3 171-182
allfields_unstemmed	10.37349/etat.2020.00011 doi (DE-627)DOAJ061689122 (DE-599)DOAJ79312cdaaf644f7183b9e74b8902906e DE-627 ger DE-627 rakwb eng RC31-1245 Antonella Pietragalla verfasserin aut Integration of PARP-inhibitors in ovarian cancer therapy 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Poly-ADP-ribose polymerase inhibitors (PARP-I) represent one of the most attractive and promising class of biological agents studied both in relapsed ovarian cancer (OC) and in the advanced setting. The availability of this new class of drugs has changed the clinical management of OC ensuring an unprecedented advance in such an aggressive cancer. Three oral PARP-I are currently available: olaparib, niraparib and rucaparib. Another two are in active clinical exploration: veliparib and talazoparib. Here the authors report clinical data with PARP-I with a particular emphasis on the phase II and III trials that support PARP-I approval by regulatory agencies in OC patients. parp-inhibitors ovarian cancer brca1 and 2 homologous recombination deficiency dna repair Internal medicine Francesca Ciccarone verfasserin aut Camilla Nero verfasserin aut Giovanni Scambia verfasserin aut Domenica Lorusso verfasserin aut Gennaro Daniele verfasserin aut In Exploration of Targeted Anti-tumor Therapy Open Exploration Publishing Inc., 2021 1(2020), 3, Seite 171-182 (DE-627)174398264X 26923114 nnns volume:1 year:2020 number:3 pages:171-182 https://doi.org/10.37349/etat.2020.00011 kostenfrei https://doaj.org/article/79312cdaaf644f7183b9e74b8902906e kostenfrei https://www.explorationpub.com/Journals/etat/Article/100211 kostenfrei https://doaj.org/toc/2692-3114 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 1 2020 3 171-182
allfieldsGer	10.37349/etat.2020.00011 doi (DE-627)DOAJ061689122 (DE-599)DOAJ79312cdaaf644f7183b9e74b8902906e DE-627 ger DE-627 rakwb eng RC31-1245 Antonella Pietragalla verfasserin aut Integration of PARP-inhibitors in ovarian cancer therapy 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Poly-ADP-ribose polymerase inhibitors (PARP-I) represent one of the most attractive and promising class of biological agents studied both in relapsed ovarian cancer (OC) and in the advanced setting. The availability of this new class of drugs has changed the clinical management of OC ensuring an unprecedented advance in such an aggressive cancer. Three oral PARP-I are currently available: olaparib, niraparib and rucaparib. Another two are in active clinical exploration: veliparib and talazoparib. Here the authors report clinical data with PARP-I with a particular emphasis on the phase II and III trials that support PARP-I approval by regulatory agencies in OC patients. parp-inhibitors ovarian cancer brca1 and 2 homologous recombination deficiency dna repair Internal medicine Francesca Ciccarone verfasserin aut Camilla Nero verfasserin aut Giovanni Scambia verfasserin aut Domenica Lorusso verfasserin aut Gennaro Daniele verfasserin aut In Exploration of Targeted Anti-tumor Therapy Open Exploration Publishing Inc., 2021 1(2020), 3, Seite 171-182 (DE-627)174398264X 26923114 nnns volume:1 year:2020 number:3 pages:171-182 https://doi.org/10.37349/etat.2020.00011 kostenfrei https://doaj.org/article/79312cdaaf644f7183b9e74b8902906e kostenfrei https://www.explorationpub.com/Journals/etat/Article/100211 kostenfrei https://doaj.org/toc/2692-3114 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 1 2020 3 171-182
allfieldsSound	10.37349/etat.2020.00011 doi (DE-627)DOAJ061689122 (DE-599)DOAJ79312cdaaf644f7183b9e74b8902906e DE-627 ger DE-627 rakwb eng RC31-1245 Antonella Pietragalla verfasserin aut Integration of PARP-inhibitors in ovarian cancer therapy 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Poly-ADP-ribose polymerase inhibitors (PARP-I) represent one of the most attractive and promising class of biological agents studied both in relapsed ovarian cancer (OC) and in the advanced setting. The availability of this new class of drugs has changed the clinical management of OC ensuring an unprecedented advance in such an aggressive cancer. Three oral PARP-I are currently available: olaparib, niraparib and rucaparib. Another two are in active clinical exploration: veliparib and talazoparib. Here the authors report clinical data with PARP-I with a particular emphasis on the phase II and III trials that support PARP-I approval by regulatory agencies in OC patients. parp-inhibitors ovarian cancer brca1 and 2 homologous recombination deficiency dna repair Internal medicine Francesca Ciccarone verfasserin aut Camilla Nero verfasserin aut Giovanni Scambia verfasserin aut Domenica Lorusso verfasserin aut Gennaro Daniele verfasserin aut In Exploration of Targeted Anti-tumor Therapy Open Exploration Publishing Inc., 2021 1(2020), 3, Seite 171-182 (DE-627)174398264X 26923114 nnns volume:1 year:2020 number:3 pages:171-182 https://doi.org/10.37349/etat.2020.00011 kostenfrei https://doaj.org/article/79312cdaaf644f7183b9e74b8902906e kostenfrei https://www.explorationpub.com/Journals/etat/Article/100211 kostenfrei https://doaj.org/toc/2692-3114 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 1 2020 3 171-182
language	English
source	In Exploration of Targeted Anti-tumor Therapy 1(2020), 3, Seite 171-182 volume:1 year:2020 number:3 pages:171-182
sourceStr	In Exploration of Targeted Anti-tumor Therapy 1(2020), 3, Seite 171-182 volume:1 year:2020 number:3 pages:171-182
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	parp-inhibitors ovarian cancer brca1 and 2 homologous recombination deficiency dna repair Internal medicine
isfreeaccess_bool	true
container_title	Exploration of Targeted Anti-tumor Therapy
authorswithroles_txt_mv	Antonella Pietragalla @@aut@@ Francesca Ciccarone @@aut@@ Camilla Nero @@aut@@ Giovanni Scambia @@aut@@ Domenica Lorusso @@aut@@ Gennaro Daniele @@aut@@
publishDateDaySort_date	2020-01-01T00:00:00Z
hierarchy_top_id	174398264X
id	DOAJ061689122
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ061689122</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230309013236.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230228s2020 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.37349/etat.2020.00011</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ061689122</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ79312cdaaf644f7183b9e74b8902906e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC31-1245</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Antonella Pietragalla</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Integration of PARP-inhibitors in ovarian cancer therapy</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Poly-ADP-ribose polymerase inhibitors (PARP-I) represent one of the most attractive and promising class of biological agents studied both in relapsed ovarian cancer (OC) and in the advanced setting. The availability of this new class of drugs has changed the clinical management of OC ensuring an unprecedented advance in such an aggressive cancer. Three oral PARP-I are currently available: olaparib, niraparib and rucaparib. Another two are in active clinical exploration: veliparib and talazoparib. Here the authors report clinical data with PARP-I with a particular emphasis on the phase II and III trials that support PARP-I approval by regulatory agencies in OC patients.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">parp-inhibitors</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">ovarian cancer</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">brca1 and 2</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">homologous recombination deficiency</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">dna repair</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Internal medicine</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Francesca Ciccarone</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Camilla Nero</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Giovanni Scambia</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Domenica Lorusso</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Gennaro Daniele</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Exploration of Targeted Anti-tumor Therapy</subfield><subfield code="d">Open Exploration Publishing Inc., 2021</subfield><subfield code="g">1(2020), 3, Seite 171-182</subfield><subfield code="w">(DE-627)174398264X</subfield><subfield code="x">26923114</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:1</subfield><subfield code="g">year:2020</subfield><subfield code="g">number:3</subfield><subfield code="g">pages:171-182</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.37349/etat.2020.00011</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/79312cdaaf644f7183b9e74b8902906e</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.explorationpub.com/Journals/etat/Article/100211</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2692-3114</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">1</subfield><subfield code="j">2020</subfield><subfield code="e">3</subfield><subfield code="h">171-182</subfield></datafield></record></collection>
callnumber-first	R - Medicine
author	Antonella Pietragalla
spellingShingle	Antonella Pietragalla misc RC31-1245 misc parp-inhibitors misc ovarian cancer misc brca1 and 2 misc homologous recombination deficiency misc dna repair misc Internal medicine Integration of PARP-inhibitors in ovarian cancer therapy
authorStr	Antonella Pietragalla
ppnlink_with_tag_str_mv	@@773@@(DE-627)174398264X
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut aut aut aut
collection	DOAJ
remote_str	true
callnumber-label	RC31-1245
illustrated	Not Illustrated
issn	26923114
topic_title	RC31-1245 Integration of PARP-inhibitors in ovarian cancer therapy parp-inhibitors ovarian cancer brca1 and 2 homologous recombination deficiency dna repair
topic	misc RC31-1245 misc parp-inhibitors misc ovarian cancer misc brca1 and 2 misc homologous recombination deficiency misc dna repair misc Internal medicine
topic_unstemmed	misc RC31-1245 misc parp-inhibitors misc ovarian cancer misc brca1 and 2 misc homologous recombination deficiency misc dna repair misc Internal medicine
topic_browse	misc RC31-1245 misc parp-inhibitors misc ovarian cancer misc brca1 and 2 misc homologous recombination deficiency misc dna repair misc Internal medicine
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Exploration of Targeted Anti-tumor Therapy
hierarchy_parent_id	174398264X
hierarchy_top_title	Exploration of Targeted Anti-tumor Therapy
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)174398264X
title	Integration of PARP-inhibitors in ovarian cancer therapy
ctrlnum	(DE-627)DOAJ061689122 (DE-599)DOAJ79312cdaaf644f7183b9e74b8902906e
title_full	Integration of PARP-inhibitors in ovarian cancer therapy
author_sort	Antonella Pietragalla
journal	Exploration of Targeted Anti-tumor Therapy
journalStr	Exploration of Targeted Anti-tumor Therapy
callnumber-first-code	R
lang_code	eng
isOA_bool	true
recordtype	marc
publishDateSort	2020
contenttype_str_mv	txt
container_start_page	171
author_browse	Antonella Pietragalla Francesca Ciccarone Camilla Nero Giovanni Scambia Domenica Lorusso Gennaro Daniele
container_volume	1
class	RC31-1245
format_se	Elektronische Aufsätze
author-letter	Antonella Pietragalla
doi_str_mv	10.37349/etat.2020.00011
author2-role	verfasserin
title_sort	integration of parp-inhibitors in ovarian cancer therapy
callnumber	RC31-1245
title_auth	Integration of PARP-inhibitors in ovarian cancer therapy
abstract	Poly-ADP-ribose polymerase inhibitors (PARP-I) represent one of the most attractive and promising class of biological agents studied both in relapsed ovarian cancer (OC) and in the advanced setting. The availability of this new class of drugs has changed the clinical management of OC ensuring an unprecedented advance in such an aggressive cancer. Three oral PARP-I are currently available: olaparib, niraparib and rucaparib. Another two are in active clinical exploration: veliparib and talazoparib. Here the authors report clinical data with PARP-I with a particular emphasis on the phase II and III trials that support PARP-I approval by regulatory agencies in OC patients.
abstractGer	Poly-ADP-ribose polymerase inhibitors (PARP-I) represent one of the most attractive and promising class of biological agents studied both in relapsed ovarian cancer (OC) and in the advanced setting. The availability of this new class of drugs has changed the clinical management of OC ensuring an unprecedented advance in such an aggressive cancer. Three oral PARP-I are currently available: olaparib, niraparib and rucaparib. Another two are in active clinical exploration: veliparib and talazoparib. Here the authors report clinical data with PARP-I with a particular emphasis on the phase II and III trials that support PARP-I approval by regulatory agencies in OC patients.
abstract_unstemmed	Poly-ADP-ribose polymerase inhibitors (PARP-I) represent one of the most attractive and promising class of biological agents studied both in relapsed ovarian cancer (OC) and in the advanced setting. The availability of this new class of drugs has changed the clinical management of OC ensuring an unprecedented advance in such an aggressive cancer. Three oral PARP-I are currently available: olaparib, niraparib and rucaparib. Another two are in active clinical exploration: veliparib and talazoparib. Here the authors report clinical data with PARP-I with a particular emphasis on the phase II and III trials that support PARP-I approval by regulatory agencies in OC patients.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
container_issue	3
title_short	Integration of PARP-inhibitors in ovarian cancer therapy
url	https://doi.org/10.37349/etat.2020.00011 https://doaj.org/article/79312cdaaf644f7183b9e74b8902906e https://www.explorationpub.com/Journals/etat/Article/100211 https://doaj.org/toc/2692-3114
remote_bool	true
author2	Francesca Ciccarone Camilla Nero Giovanni Scambia Domenica Lorusso Gennaro Daniele
author2Str	Francesca Ciccarone Camilla Nero Giovanni Scambia Domenica Lorusso Gennaro Daniele
ppnlink	174398264X
callnumber-subject	RC - Internal Medicine
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.37349/etat.2020.00011
callnumber-a	RC31-1245
up_date	2024-07-03T22:10:38.872Z
_version_	1803597527251943424
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ061689122</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230309013236.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230228s2020 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.37349/etat.2020.00011</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ061689122</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ79312cdaaf644f7183b9e74b8902906e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC31-1245</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Antonella Pietragalla</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Integration of PARP-inhibitors in ovarian cancer therapy</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Poly-ADP-ribose polymerase inhibitors (PARP-I) represent one of the most attractive and promising class of biological agents studied both in relapsed ovarian cancer (OC) and in the advanced setting. The availability of this new class of drugs has changed the clinical management of OC ensuring an unprecedented advance in such an aggressive cancer. Three oral PARP-I are currently available: olaparib, niraparib and rucaparib. Another two are in active clinical exploration: veliparib and talazoparib. Here the authors report clinical data with PARP-I with a particular emphasis on the phase II and III trials that support PARP-I approval by regulatory agencies in OC patients.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">parp-inhibitors</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">ovarian cancer</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">brca1 and 2</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">homologous recombination deficiency</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">dna repair</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Internal medicine</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Francesca Ciccarone</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Camilla Nero</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Giovanni Scambia</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Domenica Lorusso</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Gennaro Daniele</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Exploration of Targeted Anti-tumor Therapy</subfield><subfield code="d">Open Exploration Publishing Inc., 2021</subfield><subfield code="g">1(2020), 3, Seite 171-182</subfield><subfield code="w">(DE-627)174398264X</subfield><subfield code="x">26923114</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:1</subfield><subfield code="g">year:2020</subfield><subfield code="g">number:3</subfield><subfield code="g">pages:171-182</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.37349/etat.2020.00011</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/79312cdaaf644f7183b9e74b8902906e</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.explorationpub.com/Journals/etat/Article/100211</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2692-3114</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">1</subfield><subfield code="j">2020</subfield><subfield code="e">3</subfield><subfield code="h">171-182</subfield></datafield></record></collection>
score	7.4020653

Nicht das Richtige dabei?

Schreiben Sie uns!

Integration of PARP-inhibitors in ovarian cancer therapy

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?